{
    "clinical_study": {
        "@rank": "6447", 
        "arm_group": [
            {
                "arm_group_label": "prasugrel", 
                "arm_group_type": "Experimental", 
                "description": "prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up"
            }, 
            {
                "arm_group_label": "clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare reduced-dose prasugrel and standard dose\n      clopidogrel in patients older than 74 years with ACS, including non-ST-elevation (NSTEACS)\n      and ST-elevation (STEMI) patients, undergoing early PCI. The primary endpoint of the trial\n      will be the one-year composite of (all-cause)death, myocardial infarction, stroke and\n      re-hospitalization due to cardiovascular reasons or bleeding."
        }, 
        "brief_title": "The Elderly ACS II Trial", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Coronary Syndrome", 
            "Coronary Arteriosclerosis", 
            "Myocardial Ischemia", 
            "Cardiovascular Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arteriosclerosis", 
                "Cardiovascular Diseases", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Ischemia", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Patients >74 years of age hospitalized for an ACS, with or without STE, with an onset of\n        symptoms during the previous 72 hours, and candidates to an early PCI.\n\n          -  STEMI patients may be randomized upon first diagnosis, provided they do not meet any\n             exclusion criteria. STEMI patients should not exceed 50 percent of the global\n             population of the study\n\n          -  Eligible NSTEACS patients may be randomized after coronary angiography. To be\n             eligible, NSTEACS patients must have at least one of the following characteristics:\n\n               -  elevated troponin levels;\n\n               -  diabetes mellitus;\n\n               -  prior MI;\n\n               -  at least one new ischemic episode while on standard treatment during the index\n                  hospitalization;\n\n               -  ACS due to stent thrombosis.\n\n        Exclusion Criteria:\n\n          -  History of stroke or transient ischemic attack (TIA)\n\n          -  Gastrointestinal or genitourinary bleeding of clinical significance within 6 weeks\n             prior to randomization.\n\n          -  Hemoglobin level on admission <10 g/dl, unless this is considered to be secondary to\n             renal dysfunction or known myelodysplasia.\n\n          -  Secondary causes of acute myocardial ischemia.\n\n          -  Known current platelet count < 90,000 cells/mL.\n\n          -  Ongoing oral anticoagulant treatment or an INR known to be >1.5 at the time of\n             screening.\n\n          -  Concomitant severe obstructive lung disease, malignancy or neurologic deficit\n             limiting follow-up or adherence to the study protocol.\n\n          -  Participation in any phase of another clinical research study involving the\n             evaluation of another investigational drug or device within 30 days prior to\n             randomization\n\n          -  Inability to give at least verbal informed consent to the study.\n\n          -  Contraindications to the use of clopidogrel or prasugrel as per package leaflet."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "75 Years"
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777503", 
            "org_study_id": "EudraCT Number: 2012-002882-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "prasugrel", 
                "description": "prasugrel 5 mg o.d.", 
                "intervention_name": "prasugrel", 
                "intervention_type": "Drug", 
                "other_name": "Efient"
            }, 
            {
                "arm_group_label": "clopidogrel", 
                "description": "75 mg o.d.", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Plavix"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Prasugrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute coronary syndrome", 
            "elderly", 
            "percutaneous revascularization", 
            "antiaggregant drugs"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "stefano.deservi@ao-legnano.it", 
                    "last_name": "Stefano De Servi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Legnano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20025"
                    }, 
                    "name": "Azienda Ospedaliera \"Ospedale Civile di Legnano\""
                }, 
                "investigator": {
                    "last_name": "Stefano De Servi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "s.savonitto@ospedale.lecco.it", 
                    "last_name": "Stefano Savonitto, MD", 
                    "phone": "+39-0341-489490"
                }, 
                "facility": {
                    "address": {
                        "city": "Reggio Emilia", 
                        "country": "Italy", 
                        "zip": "42123"
                    }, 
                    "name": "Arcispedale Santa Maria Nuova- IRCCS"
                }, 
                "investigator": {
                    "last_name": "Stefano Savonitto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)", 
        "overall_contact": {
            "email": "s.savonitto@ospedale.lecco.it", 
            "last_name": "Stefano Savonitto, MD", 
            "phone": "+39-0341-489490"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The composite of all-cause mortality, myocardial infarction (MI), disabling stroke and re-hospitalization for cardiovascular causes or bleeding within one year", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777503"
        }, 
        "responsible_party": {
            "investigator_affiliation": "A. Manzoni Hospital", 
            "investigator_full_name": "StefanoSavonitto", 
            "investigator_title": "dept of division of Cardiology - Manzoni Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "definition of major bleeding:\n- Bleeding Academic Research Consortium (BARC) type 2 or 3 bleeding within 1 year (for bleedings occurring during index or subsequent hospitalizations)\n\u00b7 BARC type IV bleeding within 1 year", 
            "measure": "The composite of burden of recurrent cardiovascular (CV) events, CV mortality, all-cause mortality and MI, major bleeding, any stroke, total number of days spent in hospital.", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Arcispedale Santa Maria Nuova-IRCCS", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "ANMCO Italian Association of Hospital Cardiologist", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Italian Society of Invasive Cardiology", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Arcispedale Santa Maria Nuova-IRCCS", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}